Abstract
Obesity is established as a key correlate of severe SARS-CoV-2 outcomes. Multiple other epidemiological and immunological features are less well-defined including if obesity enhances susceptibility to SARS-CoV-2 infection, influences symptom phenotype, or impedes or alters the immune response to infection. Given the substantial global burden of obesity and given these uncertainties, we examined the epidemiology and immunology of obesity and SARS-CoV-2.
Methods Industry employees were invited to participate in a prospective SARS-CoV-2 serology-based cohort study. Blood and baseline survey measures that included demographics, comorbidities, and prior COVID-19 compatible symptoms were collected. Serological testing and interim symptom reporting were conducted monthly. SARS-CoV-2 immunoassays included an IgG ELISA targeting the spike RBD, multiarray Luminex targeting 20 viral antigens, pseudovirus neutralization, and T cell ELISPOT assays. Unadjusted and adjusted analyses were used to identify differences in seroprevalence, clinical features, and immune parameters by BMI.
Results Of 4469 individuals enrolled, 322 (7.21%) were seropositive. Adjusted seroprevalence was non-significantly lower with higher BMI. Obesity was associated with increased reporting of fever (OR 3.43 [95% CI 1.58-7.60]) and multiple other symptoms and aggregate measures. There were no identifiable differences in immune response between obese and non-obese individuals.
Discussion We present benchmark data from a prospective serology-based cohort on the immunoepidemiology of BMI and SARS-CoV-2. Our findings suggest obesity is not linked to an increased risk of SARS-CoV-2 infection; that symptom phenotype is strongly influenced by obesity; and that despite evidence of obesity-associated immune dysregulation in severe COVID-19, there is no evidence of a muted or suppressed immune response across multiple immune measures among non-severe infections.
Competing Interest Statement
GA is a founder of Seromyx Systems Inc., a company developing platform technology that describes the antibody immune response. GAs interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. PS is a co-founder of, shareholder in, and advisor to Sherlock Biosciences, Inc, as well as a Board member of and shareholder in Danaher Corporation. MJG, SB, YH, JR, EP, BM, ASM and ERM are employees of Space Exploration Technologies Corp. All other authors have declared that no conflict of interest exists.
Funding Statement
We acknowledge funding support from Space Exploration Technologies Corporation, the Brigham and Womens Department of Emergency Medicine, the Ragon Institute of MGH, MIT and Harvard, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the NIH (3R37AI080289-11S1), FDA HHSF223201810172C, and the Gates foundation Global Health Vaccine Accelerator Platform funding. EJN is supported by the CDC (U01 GH002238). SMS was partially supported by the US Food and Drug Administration (HHSF223201810172C). DAL was partially supported by the National Institute for Allergy and Infectious Disease (U19 AI135995).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Western Institutional Review Board. The use of de-identified data and biological samples was approved by the Mass General Brigham Healthcare Institutional Review Board. All participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author, EJN. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
